Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danvatirsen plus pembrolizumab in recurrent/metastatic HNSCC
NCT05814666Phase 2Terminated
- Sponsor
- Flamingo Therapeutics
- Start
- May 2023
- Primary completion
- Aug 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of danvatirsen in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Flamingo Therapeutics. Primary endpoint: Confirmed Objective Response Rate at 18 months. Started May 2023; status: terminated.
02
Drugs
danvatirsen
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05814666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05814666.